This content is machine translated Non-small cell lung cancer (NSCLC) Treatment strategies in metastatic ALK-positive and ROS1-positive NSCLC. The therapy of ALK-positive or ROS1-positive NSCLC has evolved greatly in recent years with the availability of various ALK or ROS1 inhibitors. This CME will summarize and discuss the current…
View Post 5 min This content is machine translated ESMO in Copenhagen and Singapore Immunotherapy puts lung cancer experts in turmoil Pembrolizumab returned to the international stage of lung cancer therapy with a thunderclap during the presentation of the KEYNOTE 024 trial at the 2016 ESMO Congress in Copenhagen. Lectures on…
